Physician profile
Vrusha Patel
NPI 1881390656
$1,106.24
in general payments reported to CMS, 2019-2025
21 companies · $503 in 2025
The $503 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $335 · 2024: $268 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.08 | 2023-2025 | |
| Lilly USA, LLC | $158.86 | 2023-2025 | Mounjaro, Kisunla, Trulicity |
| Novo Nordisk INC | $104.79 | 2024-2025 | Ozempic |
| Eisai INC. | $82.73 | 2025 | |
| Exact Sciences Corporation | $60.18 | 2025 | The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.83 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $51.15 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $46.90 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $41.15 | 2023-2024 | Rexulti |
| Lundbeck LLC | $36.80 | 2023-2024 | Rexulti |
| Amgen INC. | $34.25 | 2025 | Repatha, Otezla, Evenity |
| Inogen, INC. | $27.48 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Scilex Pharmaceuticals INC. | $25.54 | 2023 | Ztlido |
| Lexicon Pharmaceuticals, INC. | $23.89 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $21.14 | 2023 | Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.13 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $18.83 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $16.25 | 2023 | |
| Aimmune Therapeutics, INC. | $14.69 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2023 | Xifaxan |
| Dexcom, INC. | $12.84 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vrusha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.